A Randomized, Open-Label, Active-Controlled, Parallel-Group,Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in ombination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Randomized, Open-Label, Active-Controlled, Parallel-Group,Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in ombination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Albiglutide (Primary) ; Insulin glargine; Insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms Harmony-6
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Sep 2016 Results of post-hoc pooled analysis from HARMONY 1-7 trials assessing the relationship between renal function and change in HbA 1c presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top